Abstract
Polo-like kinase 1 (Plk1) is a decisive enzyme with its multifunctional activity in cell cycle progression especially mitosis. The over expression of Plk1 in broad spectrum of cancer types turns into a promising therapeutic target against cancer. In the present study, several ligand based pharmacophore models and atom based 3D-QSAR models have been generated using a series of 49 thiazole and thiophene derivatives with well prescribed Plk1 inhibitory activity. From the generated models, the AADRR hypothesis associated with an atom based 3D-QSAR model provided a satisfactory statistical significance containing predictive ability of 40 training set (R2 = 0.9539, SD = 0.1789, F = 113.8) and nine test set (Q2 = 0.4868, RMSE = 0.5333, Pearson R = 0.7114) molecules. The Hypothesis, AADRR explains the salient structural features of the molecules and the developed 3D-QSAR model points out the effect of hydrophobic groups, electron withdrawing groups and H-bond donor groups on Plk1 inhibition for the most active compound 47. The results were further supported by molecular docking studies, which explain the hydrogen bond interactions and binding mode of the ligands with Plk1. These molecular modelling results are expected to be useful for further design of active Plk1 inhibitors.
Keywords: 3D-QSAR, docking, pharmacophore modeling, Polo-like kinase 1 (Plk1), thiazole, thiophene.
Combinatorial Chemistry & High Throughput Screening
Title:Ligand-Based Pharmacophore Modeling, Atom-Based 3D-QSAR and Molecular Docking Studies on Substituted Thiazoles and Thiophenes as Polo-Like Kinase 1 (Plk1) Inhibitors
Volume: 17 Issue: 10
Author(s): Rajasekhar Chekkara, Venkata Reddy Gorla, Ethiraj Susithra and Sobha Rani Tenkayala
Affiliation:
Keywords: 3D-QSAR, docking, pharmacophore modeling, Polo-like kinase 1 (Plk1), thiazole, thiophene.
Abstract: Polo-like kinase 1 (Plk1) is a decisive enzyme with its multifunctional activity in cell cycle progression especially mitosis. The over expression of Plk1 in broad spectrum of cancer types turns into a promising therapeutic target against cancer. In the present study, several ligand based pharmacophore models and atom based 3D-QSAR models have been generated using a series of 49 thiazole and thiophene derivatives with well prescribed Plk1 inhibitory activity. From the generated models, the AADRR hypothesis associated with an atom based 3D-QSAR model provided a satisfactory statistical significance containing predictive ability of 40 training set (R2 = 0.9539, SD = 0.1789, F = 113.8) and nine test set (Q2 = 0.4868, RMSE = 0.5333, Pearson R = 0.7114) molecules. The Hypothesis, AADRR explains the salient structural features of the molecules and the developed 3D-QSAR model points out the effect of hydrophobic groups, electron withdrawing groups and H-bond donor groups on Plk1 inhibition for the most active compound 47. The results were further supported by molecular docking studies, which explain the hydrogen bond interactions and binding mode of the ligands with Plk1. These molecular modelling results are expected to be useful for further design of active Plk1 inhibitors.
Export Options
About this article
Cite this article as:
Chekkara Rajasekhar, Gorla Reddy Venkata, Susithra Ethiraj and Tenkayala Rani Sobha, Ligand-Based Pharmacophore Modeling, Atom-Based 3D-QSAR and Molecular Docking Studies on Substituted Thiazoles and Thiophenes as Polo-Like Kinase 1 (Plk1) Inhibitors, Combinatorial Chemistry & High Throughput Screening 2014; 17 (10) . https://dx.doi.org/10.2174/1386207317666141024152910
DOI https://dx.doi.org/10.2174/1386207317666141024152910 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design The Cross-talk between Tristetraprolin and Cytokines in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Significance of Transferrin Receptors in Oncology: the Development of Functional Nano-based Drug Delivery Systems
Current Drug Delivery Novel Possible Pharmaceutical Research Tools: Stem Cells, Gene Delivery and their Combination
Current Pharmaceutical Design Salen Mn Complexes are Superoxide Dismutase/Catalase Mimetics that Protect the Mitochondria
Current Inorganic Chemistry (Discontinued) Boronated DNA-Binding Compounds as Potential Agents for Boron Neutron Capture Therapy
Mini-Reviews in Medicinal Chemistry Polymeric Nanoparticles of FMISO: Are Nano-Radiopharmaceuticals Better Than Conventional Ones?
Current Radiopharmaceuticals Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy Deep Tissue Optical and Optoacoustic Molecular Imaging Technologies for Pre-Clinical Research and Drug Discovery
Current Pharmaceutical Biotechnology New Insights into Neoangiogenesis and Breast Cancer Development and Progression
Current Angiogenesis (Discontinued) Resisting the Resistance in Cancer: Cheminformatics Studies on Short- Path Base Excision Repair Pathway Antagonists Using Supervised Learning Approaches
Combinatorial Chemistry & High Throughput Screening Prospects of Molecularly-Targeted Therapies for Cervical Cancer Treatment
Current Drug Targets The Roles of Parathyroid Hormone and Calcitonin in Bone Remodeling: Prospects for Novel Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Minimally Invasive Transoral Surgical Treatment for Oropharyngeal Carcinoma
Current Cancer Therapy Reviews STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy Trifluoroibuprofen Inhibits α-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in vivo Tumor Growth in Aggressive Prostate Cancer Models
Anti-Cancer Agents in Medicinal Chemistry The Next Step in Voice Assessment: High-Speed Digital Endoscopy and Objective Evaluation
Current Bioinformatics Patent Selections
Recent Patents on Biomarkers